Curis initiated with a Buy at Truist

Truist initiated coverage of Curis with a Buy rating and $26 price target. Emavusertib “works” in AML/MDS and lymphoma and its largest opportunity is CLL where BTKs are the standard of care, the analyst tells investors. Phase 1/2 data in 2024 “should show CRIS is a potential take-out target because it is in big pharma’s best interest to develop the drug early,” the analyst tells investors.